Loading…
Leading Chinese in-vitro diagnostics maker selling immunoassay and chemistry analyzers plus reagents to hospital labs.
Leading Chinese in-vitro diagnostics maker selling immunoassay and chemistry analyzers plus reagents to hospital labs.
Places analyzers in hospital labs and earns recurring revenue from the reagents consumed on every test, which carry more of the profit than the instrument. Hospital buying runs largely through public procurement and tenders.
In one line: A Chinese Abbott Diagnostics/Roche Diagnostics for IVD.
Moat: narrow (installed base, switching costs). Analyzer-reagent lock-in once a hospital lab adopts its instrument platform.
Headquarters: Zhengzhou, Henan, China · Founded: 1998 · Employees: 5,700
Size Autobio Diagnostics (603658.SS) is a China Health Care company (Medical Specialties) with a market value of $3.41B, the 761st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥39.76 on 6 Nov 2026.
Performance Over six months the shares gained 18.7%, against +6.2% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 2.9% over the last twelve months (peer median +6.2%); the operating margin is 25.4% (peer median 9.5%).
Valuation It trades at 20.6× forward earnings against a peer median of 26.8× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.34B | CN¥4.19B | CN¥4.44B | CN¥4.39B | CN¥4.40B |
| Revenue growth | — | -6% | +1% | 0% | — |
| Gross profit | CN¥3.21B | CN¥2.59B | CN¥2.76B | CN¥2.71B | CN¥2.49B |
| EBITDA | n/a | CN¥1.56B | CN¥1.61B | CN¥1.66B | CN¥1.58B |
| Net income | CN¥1.06B | CN¥1.07B | CN¥1.19B | CN¥1.22B | CN¥1.17B |
| Free cash flow | CN¥539M | CN¥738M | CN¥649M | CN¥569M | CN¥629M |
| Capital expenditure | CN¥494M | CN¥604M | CN¥664M | CN¥900M | CN¥938M |
| Total debt | CN¥972M | CN¥996M | CN¥1.04B | CN¥1.04B | CN¥873M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Autobio Diagnostics 603658.SS | $3.41B | +19% | +3% | 25% | 20.6× | -0.3% |
| Abbott Laboratories ABT | $190B | +30% | +10% | 14% | 18.8× | 5.6% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.4B | +9% | +5% | 28% | 27.1× | 0.9% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603658.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.7% | +7.3% | 3rd highest of 21 |
| 6-month return | +18.7% | +6.2% | 9th highest of 21 |
| Distance from 52-week high | -1.0% | -30.9% | highest of 21 |
| Revenue growth (TTM) | +2.9% | +6.2% | 6th lowest of 19 |
| Operating margin | 25.4% | 9.5% | highest of 19 |
| Forward P/E | 20.6× | 26.8× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -0.3% | 12.1% | 3rd least demanding of 17 |
| Growth delivered (Del g) | +7.2% | +8.5% | 7th lowest of 17 |
| Hurdle (Req g minus delivered) | -7.5 pp | +1.1 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +7.7 pp | -2.1 pp | highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Autobio Diagnostics 603658.SS | China | $3.41B | +19% | +3% | 25% | 20.6× | -0.3% | +7.2% |
| MGI Tech 688114.SS | China | $3.42B | +9% | +2% | -7% | n/a | 46.5% | -0.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.42B | -12% | -1% | 13% | 26.3× | 9.6% | -4.2% |
| Ambu A/S AMBU-B.CO | Denmark | $3.42B | +40% | +5% | 11% | 28.1× | 12.6% | +11.1% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $3.36B | -25% | +5% | 15% | 15.4× | 3.5% | +8.0% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 43.5× | 23.2% | -16.1% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.51B | +40% | 0% | 8% | 26.8× | 13.7% | +10.8% |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 14.9× | 6.8% | +8.9% |
| iRay Technology 688301.SS | China | $3.54B | -8% | +58% | 24% | 27.5× | n/a | n/a |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Andon Health 002432.SZ | China | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% | -7.4% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -3% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% | +11.0% |
| Stevanato STVN | United States | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% | +12.1% |
| TransMedics TMDX | United States | $3.06B | +30% | +26% | 12% | 48.5× | 35.6% | +88.2% |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | n/a | n/a | n/a |
| Axogen AXGN | United States | $2.99B | +19% | +24% | -5% | 76.5× | 48.8% | +14.9% |
| AtriCure ATRC | United States | $2.98B | +123% | +14% | 3% | 220.7× | 55.7% | +20.9% |
| iRhythm IRTC | United States | $2.97B | -25% | +26% | 1% | 182.6× | n/a | n/a |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% | +7.1% |
| Tecan TECN.SW | Switzerland | $4.05B | +91% | -4% | 1% | 40.1× | 46.9% | +3.8% |